Health ❯ Diabetes

Type 2 Diabetes

Treatment Options Medications Risk Factors Medication GLP-1 Receptor Agonists Management Prediabetes Complications Blood Sugar Management Weight Management Treatment GLP-1 Therapies Insulin Sensitivity Diagnosis Genetic Factors Obesity Medication Management Pre-Diabetes GLP-1 Agonists Management Strategies Cardiovascular Health Blood Sugar Control Clinical Trials Insulin Resistance Insulin Regulation Pre-diabetes Remission Prevention Diabetes Medications Preventive Measures Neuronal Dysfunction Treatment Advances Exercise Benefits Nervous System Dysfunction Glycemic Control A1C Levels Lifestyle Diseases Obesity Management Metabolic Dysfunction Screening Metabolic Disorders Lifestyle Management Pediatric Diabetes Cardiovascular Risk Hormone Therapy G6PD Deficiency Mounjaro Dietary Management Data Interpretation Oral Medications Inflammation Metformin Metabolic Health Continuous Glucose Monitoring Health Management Treatment Innovations Pharmaceutical Treatments Hyperglycemia Medication Impact Dietary Factors Glucose Monitoring Treatment Methods Innovative Treatments Nutritional Deficiencies Weight Loss Medication Use Differences from Type 1 Colorectal Cancer Semaglutide Diabetes Management Diabetes Remission Comorbidities Gestational Diabetes Metabolic Syndrome Blood Sugar Regulation Hormonal Treatments Dietary Changes Comparative Risk Medication Benefits Cholesterol Levels Dietary Impact Glucose Regulation Obesity-related Conditions Diabetes Treatments Pancreatic β-cells Therapeutics

Lilly Urges Recall After Finding New Impurity in Compounded Tirzepatide With B12

The warning focuses on mass-marketed 'personalized' versions sold outside FDA review.

Stories older than 24h

GLP-1 Drugs Plus Healthy Habits Linked to Lower Heart Risk in Large VA Diabetes Study

Study Finds Waist-to-Height Ratio Outperforms BMI for Flagging Diabetes Risk in U.S. Youth

Novo’s Triple-Hormone Obesity Drug UBT251 Hits 19.7% Mean Weight Loss in China Phase 2

Wegovy Pill Debuts to Strong U.S. Demand as Next‑Gen Obesity Drugs Near Decisions

After-Meal Blood Sugar Spikes Tied to 69% Higher Alzheimer’s Risk, Large Genetic Study Finds

Daylight Exposure Improves Glucose Stability in Controlled Type 2 Diabetes Trial

Lilly Files Orforglipron Obesity Pill With FDA After Trial Shows Weight-Loss Maintenance

Lilly’s Triple-Agonist Retatrutide Shows Major Phase 3 Weight Loss as Grey-Market Use Prompts Warning

Meta-Analysis Finds GLP-1 Drugs Show Little Short-Term Impact on Obesity-Linked Cancer Risk

Gut Microbe Molecule TMA Inhibits IRAK4, Easing Diet-Driven Inflammation in Diabetes Models

Brain Maps of GLP-1 Drugs Point to Paths for Weight Loss Without Nausea

GLP-1 Drugs Linked to Lower Five-Year Death Risk in Colon Cancer, UCSD Study Finds

Randomized Trial Finds Metformin Dulls Key Gains From Exercise

Real-World Study Finds Semaglutide and Tirzepatide Cut Cardiovascular Risk in Type 2 Diabetes

Global Study Finds Chronic Kidney Disease Now a Top-10 Killer, Affecting Nearly 800 Million

GLP-1 Drugs Plus Healthy Habits Linked to Bigger Heart Risk Drop in Veterans With Type 2 Diabetes

Lilly’s Oral GLP-1 Orforglipron Beats Farxiga and Placebo in Two Phase 3 Diabetes Trials

Study Finds CGMs Track HbA1c in Type 2 Diabetes but Not in People Without Diabetes

Common Genetic Variant Skews HbA1c, Delaying Diabetes Diagnosis in Black and South Asian Men